D2C7-IT

Phase 1Small molecule

DDarell Bigner

D2C7-IT is one of 80 small molecule programs targeting Glioma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Malignant GliomaActive, not recruiting

GliomaPhase 1

Active, not recruiting

Malignant GliomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

394 competitors in Glioma

#DrugCompanyPhaseTrials

Paraplatin

AAvyxa

Phase 3

15 2

Trexall

Alnylam Pharmaceuticals

Phase 3

2 3

Tepadina

Alnylam Pharmaceuticals

Phase 3

1 4

Bicnu

MMelissa K Accordino

Phase 3

7 5

Vepesid

AAvyxa

Phase 3

4 6

Accutane

CConrado Roberto Hoffmann Filho

Phase 3

1 7

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 8

Ifex

BBaxter Healthcare Corporation

Phase 3

1 9

Velban

EEastern Cooperative Oncology Group

Phase 3

1 10

Selumetinib /m2

NNational Cancer Institute (NCI)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Malignant Glioma

NCT04547777

Q4 2027

Phase 1Active, not recruiting

Glioma

NCT04160494

Q4 2028

Phase 1/2Recruiting

Newly Diagnosed

NCT05734560

Q1 2030

Phase 1Recruiting

GBM

NCT06455605

Clinical

Trials by Indication[1]

Malignant Glioma2 trials

Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

Recruiting·DDarell Bigner·Phase 1·NCT04547777·90 enrolled

Phase I Single-Center, Dose Escalation Study of D2C7-IT Administered Intratumorally Via Convection-Enhanced Delivery for Adult Patients With Recurrent Malignant Glioma

Completed·DDarell Bigner·Phase 1·NCT02303678·81 enrolled

GBM1 trial

D2C7-IT + 2141-V11 Combination Post-resection in rGBM

Recruiting·DDarell Bigner·Phase 1·NCT06455605·46 enrolled

Newly Diagnosed1 trial

D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

Recruiting·DDarell Bigner·Phase 1/2·NCT05734560·50 enrolled

Glioma1 trial

D2C7-IT With Atezolizumab for Recurrent Gliomas

Active, not recruiting·DDarell Bigner·Phase 1·NCT04160494·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for D2C7-IT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — D2C7-IT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for D2C7-IT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Darell Bigner company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: DDarell Bigner

D2C7-IT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q4 2028

Q1 2030

Trials by Indication[1]

Malignant Glioma2 trials

GBM1 trial

Newly Diagnosed1 trial

Glioma1 trial

References

Drug Info

Quick Facts

Related News